306 related articles for article (PubMed ID: 26755646)
1. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
[TBL] [Abstract][Full Text] [Related]
3. The POLD1
Job A; Tatura M; Schäfer C; Lutz V; Schneider H; Lankat-Buttgereit B; Zielinski A; Borgmann K; Bauer C; Gress TM; Buchholz M; Gallmeier E
Sci Rep; 2020 Nov; 10(1):18924. PubMed ID: 33144657
[TBL] [Abstract][Full Text] [Related]
4. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
7. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
[TBL] [Abstract][Full Text] [Related]
8. Human POLD1 modulates cell cycle progression and DNA damage repair.
Song J; Hong P; Liu C; Zhang Y; Wang J; Wang P
BMC Biochem; 2015 Jun; 16():14. PubMed ID: 26087769
[TBL] [Abstract][Full Text] [Related]
9. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
10. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
[TBL] [Abstract][Full Text] [Related]
11. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
12. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
14. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.
Mohni KN; Kavanaugh GM; Cortez D
Cancer Res; 2014 May; 74(10):2835-45. PubMed ID: 24662920
[TBL] [Abstract][Full Text] [Related]
15. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
[TBL] [Abstract][Full Text] [Related]
16. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
17. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
18. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
19. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
20. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
